4 Biotech Stocks Finish Big
In this video, health care analysts David Williamson and Max Macaluso discuss some of the biggest movers at the end of last week. We have upgrades, downgrades, and clinical trial action impacting several popular stocks. Watch and find out why these stocks moved and what it means for investors.
Many investors to volatile small-cap biotechs since they hold the allure of substantial short term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
Editor's note: Novartis' Sandostatin fourth-quarter sales of $374 million are misstated as its full year sales, instead of $1.4 billion. The Fool regrets the error.
The article 4 Biotech Stocks Finish Big originally appeared on Fool.com.Dave Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.